PODOFILOX - Generic Drug Details

What are the generic sources for podofilox and what is the scope of patent protection?

Podofilox is the generic ingredient in two branded drugs marketed by Allergan, Padagis Us, Teva Branded Pharm, and Bausch And Lomb Inc, and is included in five NDAs. Additional information is available in the individual branded drug profile pages.

There are two drug master file entries for podofilox. Three suppliers are listed for this compound.

Summary for PODOFILOX

US Patents:	0
Tradenames:	2
Applicants:	4
NDAs:	5
Drug Master File Entries:	2
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	93
Clinical Trials:	1
Patent Applications:	6,781
Drug Prices:	Drug price trends for PODOFILOX
What excipients (inactive ingredients) are in PODOFILOX?	PODOFILOX excipients list
DailyMed Link:	PODOFILOX at DailyMed

See drug prices for PODOFILOX

Recent Clinical Trials for PODOFILOX

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Hyloris Developments SA	Phase 3
bioRASI, LLC	Phase 3
Dermax SA	Phase 3

See all PODOFILOX clinical trials

Pharmacology for PODOFILOX

Physiological Effect

Decreased Mitosis

US Patents and Regulatory Information for PODOFILOX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Padagis Us	PODOFILOX	podofilox	GEL;TOPICAL	211871-001	Nov 22, 2023	AB	RX	No	No
Teva Branded Pharm	CONDYLOX	podofilox	SOLUTION;TOPICAL	019795-001	Dec 13, 1990	AT	RX	Yes	Yes
Allergan	CONDYLOX	podofilox	GEL;TOPICAL	020529-001	Mar 13, 1997	AB	RX	Yes	Yes
Padagis Us	PODOFILOX	podofilox	SOLUTION;TOPICAL	075600-001	Jan 29, 2002	AT	RX	No	No
Bausch And Lomb Inc	PODOFILOX	podofilox	SOLUTION;TOPICAL	090184-001	Jul 21, 2010		DISCN	No	No

Expired US Patents for PODOFILOX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Allergan	CONDYLOX	podofilox	GEL;TOPICAL	020529-001	Mar 13, 1997	4,680,399
Allergan	CONDYLOX	podofilox	GEL;TOPICAL	020529-001	Mar 13, 1997	5,057,616

PODOFILOX Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Podofilox

Market Overview

Podofilox, a topical agent used for the treatment of external genital warts and perianal warts, is an integral part of the genital warts treatment market. Here’s a detailed look at the market dynamics and financial trajectory of podofilox.

Market Size and Growth

The genital warts treatment market, which includes podofilox, is expected to experience significant growth over the next few years. The market size is projected to increase from USD 1.79 billion in 2024 to USD 2.12 billion by 2028, with a compound annual growth rate (CAGR) of 4.4%[3].

Specific Market Projections for Genital Warts Treatment

• The global genital warts treatment market is estimated to be valued at USD 1.91 billion in 2024 and is expected to reach USD 2.72 billion by 2031, growing at a CAGR of 5.2% from 2024 to 2031[4].

Drug Type Analysis

Podofilox Market Share

Podofilox, along with podophyllin, is a key drug type in the genital warts treatment market. While imiquimod leads the market with a 38% share, podofilox and podophyllin are significant contributors. The market segmentation by drug type indicates that podofilox and podophyllin together form a substantial segment, although the exact market share of podofilox alone is not specified in the available data[1].

Treatment Analysis

Treatment Methods

Podofilox falls under the chemical destruction category of treatments for genital warts. Chemical destruction techniques, which include the use of podofilox, account for a significant portion of the market, though physical destruction methods currently hold the largest share at 45%[1].

Distribution Channel Analysis

Distribution Channels

The distribution of podofilox and other genital warts treatments is primarily through hospital pharmacies, which hold a 49% market share. Retail pharmacies and online pharmacies also play important roles, but hospital pharmacies dominate the distribution channel[1].

Regional Analysis

Global Market Distribution

The global genital warts treatment market is regionally diverse, with North America leading the market with a 38% share. Other significant regions include Europe, Asia-Pacific, South America, and the Middle East & Africa. The regional distribution indicates a broad market reach for podofilox and other treatments[1].

Drivers of Growth

Increasing Awareness and Healthcare Infrastructure

The growth of the genital warts treatment market, including the demand for podofilox, is driven by several factors:

• Increasing awareness among people about sexually transmitted diseases (STDs)[4].
• Effective drugs and medicines available for treatment[4].
• Developing healthcare infrastructure in emerging nations[4].

Technological Innovations and Global Health Initiatives

Technological innovations, the rise of telemedicine and digital health, and global health initiatives are also significant drivers. These advancements enhance the accessibility and effectiveness of treatments like podofilox[3].

Restraints and Challenges

Social Stigma and Preference for Non-Drug Therapies

Despite the growth potential, the market faces challenges such as:

• Social stigma associated with genital warts, which can reduce the demand for treatments like podofilox[4].
• Patient preference for non-drug therapies, which can impact the adoption rate of pharmaceutical treatments[4].

Financial Trajectory

Revenue Projections

The financial trajectory for the genital warts treatment market, and by extension podofilox, is positive. Here are some key financial projections:

• The market is expected to grow from USD 1.79 billion in 2024 to USD 2.12 billion by 2028[3].
• By 2031, the market is projected to reach USD 2.72 billion, growing at a CAGR of 5.2% from 2024 to 2031[4].

Pricing and Availability

Podofilox is available in various formulations, including solutions and gels, with prices varying based on the dosage form and manufacturer. For example, a 3.5ml bottle of podofilox 0.5% solution can cost around $105.99 USD[5].

Key Takeaways

• Market Growth: The genital warts treatment market, including podofilox, is expected to grow significantly, driven by increasing awareness, technological innovations, and global health initiatives.
• Drug Type: Podofilox is a key drug in the chemical destruction category, though imiquimod leads the market.
• Distribution: Hospital pharmacies dominate the distribution channels.
• Regional Analysis: North America leads the global market, with other regions also showing significant growth.
• Financial Trajectory: The market is projected to reach USD 2.72 billion by 2031, with a CAGR of 5.2% from 2024 to 2031.

FAQs

Q: What is the primary use of podofilox? A: Podofilox is primarily used for the treatment of external genital warts and perianal warts[5].

Q: What is the expected growth rate of the genital warts treatment market? A: The market is expected to grow at a CAGR of 5.2% from 2024 to 2031[4].

Q: Which distribution channel dominates the market for genital warts treatments? A: Hospital pharmacies currently hold the largest market share at 49%[1].

Q: What are the main drivers of growth for the genital warts treatment market? A: Increasing awareness, developing healthcare infrastructure, technological innovations, and global health initiatives are key drivers[3][4].

Q: What are some of the challenges facing the genital warts treatment market? A: Social stigma and patient preference for non-drug therapies are significant challenges[4].

Sources

1. Market.us: Genital Warts Treatment Market Size, Share | CAGR of 4.9% - Report ID: 77535
2. RxAbbVie: Condylox - master-uspi-podofilox
3. ResearchAndMarkets: Condyloma Acuminata Treatment Global Market Report 2024
4. Coherent Market Insights: Genital Warts Treatment Market - Price, Size, Share & Growth
5. DrugBank: Podofilox: Uses, Interactions, Mechanism of Action | DrugBank Online